Chargement en cours...
Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%–7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need f...
Enregistré dans:
| Publié dans: | Ther Clin Risk Manag |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4644179/ https://ncbi.nlm.nih.gov/pubmed/26609233 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S72943 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|